Search results for "Hepatitis B viru"

showing 6 items of 296 documents

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched

2021

Since molecules with direct-acting antiviral (DAA) became available, the landscape of the treatment of hepatitis C virus (HCV) infection has completely changed. The new drugs are extremely effective in eradicating infection, and treatment is very well tolerated with a duration of 8-12 wk. This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages, identifying some clinically relevant hot topics. First, do the rates of virological response remain as high when patients with more advanced cirrhosis are considered? Large studies have shown slightly lower but still satisfactory rates of response in these patients. Nevertheless, modified sche…

medicine.medical_specialtyHepatitis B virusHepatitis C virusHepatitis C virus/hepatitis B virus coinfection.HepacivirusHypoglycemiamedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health sciencesLiver diseasechemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinemedicineAnimalsHumansAdvanced cirrhosisDirect antiviral activityHepatitis B virusbusiness.industryHepatitis C virusCoinfectionIncidence (epidemiology)RibavirinGastroenterologyvirus diseasesMinireviewsGeneral MedicineHepatitis C Chronicmedicine.diseaseHepatitis BHepatitis Cdigestive system diseaseschemistry030220 oncology & carcinogenesisCoinfection030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessLiver cancerChickensWorld Journal of Gastroenterology
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Knowledge, Attitude and Practice of Hepatitis B Virus Infection among Dental Students and Interns in Saudi Arabia

2018

Background Hepatitis B virus (HBV) is a worldwide healthcare problem. Dental health care professionals are at a high risk of infection by HBV. The present study investigated the knowledge, attitude and practice of HBV infection among Saudi dental students and Interns in Saudi Arabia. Material and methods This was a questionnaire-based cross-sectional study. A self-administered questionnaire consisting of questions on students' knowledge, attitudes, and practices regarding HBV was used. Data of 420 participants were analyzed using SPSS (Statistical Package for Social Studies) version 22.0. Results The response rate was 84%. Overall, the participants showed fair level of knowledge about HBV, …

medicine.medical_specialtyeducationMEDLINENegative attitudemedicine.disease_cause03 medical and health sciences0302 clinical medicineHealth caremedicine030212 general & internal medicineGeneral DentistryHepatitis B virusResponse rate (survey)business.industryDental healthRisk of infectionResearchvirus diseases030206 dentistry:CIENCIAS MÉDICAS [UNESCO]digestive system diseasesCommunity and Preventive DentistryFace masksFamily medicineUNESCO::CIENCIAS MÉDICASbusinessJournal of Clinical and Experimental Dentistry
researchProduct

Isolated Anti-HBc: Significance and Management.

2019

Hepatitis B virus (HBV) infection is prevalent worldwide and is associated with dramatic levels of morbidity and mortality. Isolated anti-HBc (IAHBc) is a particular serological pattern that is commonly found in immunocompromised patients. There is ongoing debate regarding the management of patients with IAHBc. Herein, we summarize the current guidelines and the newest evidence. The frequency of IAHBc is variable, with a higher prevalence in some populations, such as persons living with HIV and others immunocompromised patients. The risk of HBV reactivation depends on host factors (including immunosuppression) and viral factors. It is now well established that immunocompromised patients can…

medicine.medical_specialtyisolated anti-HBc antibodiesmedicine.medical_treatmentHbv reactivationHBV reactivationlcsh:Medicineviral hepatitisReviewmedicine.disease_causeSerology03 medical and health sciences0302 clinical medicineInternal medicinemedicineIn patient030203 arthritis & rheumatologyHepatitis B virusimmunosuppressionbusiness.industrylcsh:Rvirus diseasesImmunosuppressionGeneral Medicinemedicine.diseasehepatitis B infectionAnti hbcVaccination030211 gastroenterology & hepatologybusinessViral hepatitismanagementJournal of clinical medicine
researchProduct

Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug us…

2011

Abstract The global spread of hepatitis B virus (HBV) and hepatitis C virus (HCV), their high chronicity rates and their progression to cirrhosis and hepatocellular carcinoma, are major public health problems. Research and intervention programmes for special population groups are needed in order to assess their infection risk and set up suitable prevention and control strategies. Aim of this paper is to give health care professionals information on HBV and HCV infections amongst migrants, drug users and prison inmates. The manuscript is an official Position Paper on behalf of the following Scientific Societies: Italian Association for the Study of the Liver (A.I.S.F.), Italian Society of In…

medicine.medical_specialtymedia_common.quotation_subjectHCV HBV vaccimantion inmatesPopulationPsychological interventionPrisonContext (language use)migrantsmedicine.disease_causeVulnerable PopulationsDrug UsersHepatitis B ChronicHealth carehcvMedicineHumanseducationPsychiatrySubstance Abuse Intravenousmedia_commonHepatitis B virusTransients and Migrantseducation.field_of_studyHepatologybusiness.industryPublic healthPrisonersVaccinationGastroenterologyvirus diseasesHepatitis C Chronicintravenous drug usersSocioeconomic FactorsPractice Guidelines as TopichbvPosition paperhbv; hcv; intravenous drug users; migrants; prison inmatesbusinessprison inmates
researchProduct

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B

2018

Background Host genetic modifiers of the natural history of chronic hepatitis B (CHB) remain poorly understood. Recently, a genome-wide association study (GWAS)-identified polymorphism in the STAT4 gene that contributes to the risk for hepatocellular carcinoma (HCC) was shown to be associated with the full spectrum of hepatitis B virus (HBV) outcomes in Asian patients. However, the functional mechanisms for this effect are unknown and the role of the variant in modulating HBV disease in Caucasians has not been investigated. Aims To determine whether STAT4 genetic variation is associated with liver injury in Caucasian patients with CHB and to investigate potential mechanisms mediating this e…

musculoskeletal diseases0301 basic medicinemedicine.medical_specialtyGenome-wide association studymedicine.disease_cause03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingimmune system diseasesInternal medicinemedicineGenetic predispositionPharmacology (medical)skin and connective tissue diseasesHepatitis B virusHepatologybusiness.industryGastroenterologyhemic and immune systemsHepatologyHepatitis Bmedicine.disease030104 developmental biologyHepatocellular carcinomaImmunologyInterleukin 12030211 gastroenterology & hepatologyViral hepatitisbusinessAlimentary Pharmacology & Therapeutics
researchProduct